Telix Pharmaceuticals Submitted Briefing Package to the US FDA

Telix Pharmaceuticals Limited (ASX: TLX) has reported that it submitted a clinical briefing package to the US FDA for its product, following the procedural guidance approval from its pre-NDA meeting.

·         TLX has completed the manufacturing and product release analytics.

·         The amended Drug Master File would be filed with FDA in January 2020.

·         TLX-591- CDx would be used for the prostate cancer.

By 1:44 PM AEDT, TLX was trading at $1.615, down by 0.31% from the previous close.

 

·         TLX has completed the manufacturing and product release analytics.

·         The amended Drug Master File would be filed with FDA in January 2020.

·         TLX-591- CDx would be used for the prostate cancer.

By 1:44 PM AEDT, TLX was trading at $1.615, down by 0.31% from the previous close.

 

-->

 

All pictures are copyright to their respective owner(s).Kalkinemedia.com does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.

 

There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

CLICK HERE FOR YOUR FREE REPORT!
   
x
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK